Literature DB >> 6318944

A familial syndrome of susceptibility to chronic active Epstein-Barr virus infection.

J H Joncas, F Ghibu, M Blagdon, S Montplaisir, I Stefanescu, J Menezes.   

Abstract

In two members of a family (daughter and father) active Epstein-Barr virus (EBV) infections persisted over periods of 4 and 3 years respectively (possibly 10 years in the father). Both had persistent splenomegaly and occasional bouts of unexplained fever but lived otherwise normal lives. The other members of the family (mother and son) were healthy. The titres of antibody to the EBV viral capsid antigen (VCA) and early antigen (EA) were extremely high in the daughter's blood, whereas the titres of antibody to the Epstein-Barr nuclear antigen were low in the daughter's blood and undetectable in the father's. Target cells of the EBV infection that were obtained from the daughter's blood were established in culture with great difficulty and showed increased expression of VCA and EA. Other immunologic investigations in the two patients revealed that the ratio of helper to suppressor T lymphocytes was inverted, natural killer-cell activity was abnormally low, lymphocyte responses to certain mitogens were depressed and there was a serum factor blocking mitogen-induced transformation. The possibility that the patients' unusual susceptibility to EBV infection represented an inherited syndrome (perhaps X-linked) is discussed.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6318944      PMCID: PMC1875355     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN: 0008-4409            Impact factor:   8.262


  11 in total

1.  Unusual prevalence of Epstein-Barr virus early antigen (EBV-EA) antibodies in ataxia telangiectasia.

Authors:  J Joncas; N Lapointe; F Gervais; M Leyritz
Journal:  J Immunol       Date:  1977-11       Impact factor: 5.422

2.  Epstein-Barr virus-related antibody patterns in ataxia-telangiectasia.

Authors:  A I Berkel; W Henle; G Henle; G Klein; F Ersoy; O Sanal
Journal:  Clin Exp Immunol       Date:  1979-02       Impact factor: 4.330

3.  Immunofluorescence in cells derived from Burkitt's lymphoma.

Authors:  G Henle; W Henle
Journal:  J Bacteriol       Date:  1966-03       Impact factor: 3.490

4.  Cellular localization of an Epstein-Barr virus (EBV)-associated complement-fixing antigen in producer and non-producer lymphoblastoid cell lines.

Authors:  B M Reedman; G Klein
Journal:  Int J Cancer       Date:  1973-05       Impact factor: 7.396

5.  Immunoregulatory T cells in varicella.

Authors:  A Bertotto; F Gentili; R Vaccaro
Journal:  N Engl J Med       Date:  1982-11-11       Impact factor: 91.245

6.  A non-x-linked syndrome with susceptibility to severe Epstein-Barr virus infections.

Authors:  G Fleisher; S Starr; N Koven; H Kamiya; S D Douglas; W Henle
Journal:  J Pediatr       Date:  1982-05       Impact factor: 4.406

7.  Immune deficiency in the X-linked lymphoproliferative syndrome. I. Epstein-Barr virus-specific defects.

Authors:  S Harada; K Sakamoto; J K Seeley; T Lindsten; T Bechtold; J Yetz; G Rogers; G Pearson; D T Purtilo
Journal:  J Immunol       Date:  1982-12       Impact factor: 5.422

8.  Epstein-Barr virus-induced diseases in boys with the X-linked lymphoproliferative syndrome (XLP): update on studies of the registry.

Authors:  D T Purtilo; K Sakamoto; V Barnabei; J Seeley; T Bechtold; G Rogers; J Yetz; S Harada
Journal:  Am J Med       Date:  1982-07       Impact factor: 4.965

9.  Abrogation of cell-mediated immunity by a serum blocking factor isolated from patients with infectious mononucleosis.

Authors:  W H Wainwright; R W Veltri; P M Sprinkle
Journal:  J Infect Dis       Date:  1979-07       Impact factor: 5.226

10.  Epstein-Barr virus antibodies in patients with ataxia-telangiectasia and other immunodeficiency diseases.

Authors:  J H Joncas; A Wills; E Reece; Z Fox
Journal:  Can Med Assoc J       Date:  1981-10-15       Impact factor: 8.262

View more
  9 in total

1.  Fatal infectious mononucleosis with staphylococcal pyoderma in a girl with hereditary immunological dysregulations.

Authors:  T Inaba; R Hanada; A Yaginuma; Y Hayashi; K Yamamoto; H Hukada
Journal:  Eur J Pediatr       Date:  1989-12       Impact factor: 3.183

2.  Risk factors in pediatric AIDS.

Authors:  J H Joncas; N Lapointe; M V O'Shaughnessy
Journal:  Can Med Assoc J       Date:  1985-03-15       Impact factor: 8.262

3.  Biomolecular analysis of a defective nontransforming Epstein-Barr virus (EBV) from a patient with chronic active EBV infection.

Authors:  C Alfieri; J H Joncas
Journal:  J Virol       Date:  1987-10       Impact factor: 5.103

Review 4.  Severe chronic active Epstein-Barr virus infection syndrome.

Authors:  M Okano; S Matsumoto; T Osato; Y Sakiyama; G M Thiele; D T Purtilo
Journal:  Clin Microbiol Rev       Date:  1991-01       Impact factor: 26.132

5.  Lytic, nontransforming Epstein-Barr virus (EBV) from a patient with chronic active EBV infection.

Authors:  C Alfieri; F Ghibu; J H Joncas
Journal:  Can Med Assoc J       Date:  1984-11-15       Impact factor: 8.262

6.  EBV Chronic Infections.

Authors:  Pizzigallo Eligio; Racciatti Delia; Gorgoretti Valeria
Journal:  Mediterr J Hematol Infect Dis       Date:  2010-08-10       Impact factor: 2.576

7.  An adult case of chronic active Epstein-Barr virus infection with interstitial pneumonitis.

Authors:  Eun-Jeong Joo; Young Eun Ha; Dong Sik Jung; Hae Suk Cheong; Yu Mi Wi; Jae-Hoon Song; Kyong Ran Peck
Journal:  Korean J Intern Med       Date:  2011-11-28       Impact factor: 2.884

8.  CD70 Deficiency due to a Novel Mutation in a Patient with Severe Chronic EBV Infection Presenting As a Periodic Fever.

Authors:  Roberta Caorsi; Marta Rusmini; Stefano Volpi; Sabrina Chiesa; Claudia Pastorino; Angela Rita Sementa; Paolo Uva; Alice Grossi; Edoardo Lanino; Maura Faraci; Francesca Minoia; Sara Signa; Paolo Picco; Alberto Martini; Isabella Ceccherini; Marco Gattorno
Journal:  Front Immunol       Date:  2018-01-29       Impact factor: 7.561

Review 9.  Chronic Active Epstein-Barr Virus Disease.

Authors:  Hiroshi Kimura; Jeffrey I Cohen
Journal:  Front Immunol       Date:  2017-12-22       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.